FujiFilm

Ripcord, Inc. is a robotic digitization company founded in 2014 and headquartered in Los Angeles, California. The company specializes in creating a platform for paperless document management, utilizing advanced technologies such as artificial intelligence, machine learning, and vision-guided robotics. Their primary product, Canopy, employs automation software to capture, enrich, and organize essential content, effectively creating a digital twin of information. By integrating sensors and software automation, Ripcord enables enterprises to enhance their business processes, improving speed, quality, and accuracy in managing important documents. The company, originally known as Ripcord Digital, Inc., rebranded in June 2017 to reflect its focus on innovative digitization solutions.

MicroChannel is a multi-award-winning business solutions and technology provider, servicing mid-sized businesses, corporate divisions and government agencies. Founded in 1995, MicroChannel assists hundreds of clients to leverage business technology for commercial success.

24M Technologies specializes in the development of energy storage systems for both grid and transportation applications. The company focuses on manufacturing lithium-ion batteries that enhance the operational reliability, economics, and efficiency of electric power systems. Its innovative approach features binder-free semisolid electrodes and unit cells, which not only improve battery performance but also eliminate the need for traditional hydro or pyrometallurgical processes in battery recycling. Additionally, 24M facilitates direct in-plant reuse of active materials at the end of a battery's life, contributing to more sustainable recycling practices and enabling clients to increase efficiency and reduce costs.

Cuorips Inc. is a medical care company based in Chuo, Japan, with an additional office in Osaka. Founded in 2017, the company focuses on the research, development, and commercialization of iPS cell-derived cardiomyocyte sheets and various cell therapeutic products. Cuorips is involved in the manufacturing and sales of cellular and tissue-based products, as well as providing contract development and manufacturing services. The company aims to advance medical treatments through innovative cell products and therapies.

Rege Nephro Co., Ltd., established in 2019 and based in Kyoto, Japan, is a biotech company focused on the research, development, production, and marketing of therapeutics for renal diseases. The company leverages induced pluripotent stem cell (iPSC) technology, sourced from the Center for iPS Cell Research and Application at Kyoto University, to create innovative treatments for kidney, liver, and pancreas conditions. Rege Nephro develops drugs that utilize core seeds technology, which includes pluripotent stem cells capable of producing erythropoietin (EPO) and specific nephron progenitor cell markers. This approach aims to minimize the reliance on dialysis among patients with renal failure by offering effective therapeutic alternatives. Additionally, the company produces kidney organoids designed for nephrotoxicity screening, facilitating drug discovery in applied research.

Nanox Imaging plc specializes in advanced imaging technology for medical, security, and telecommunications sectors. Founded in 2011 and headquartered in Gibraltar, the company focuses on transforming X-ray imaging through its innovative Nanox System, which operates under a Medical Screening As A Service (MSaaS) model. The core of Nanox's technology lies in its proprietary cold cathode technology, developed from over 20 years of research and more than $1 billion in investment. This technology utilizes unique field-effect cathodes designed with nano-scale structures to significantly enhance X-ray imaging capabilities. By transitioning from glass to silicon manufacturing processes, Nanox has achieved unprecedented power density and uniformity in its emitters. The company aims to usher X-ray imaging into the digital age, enabling novel 3D imaging systems that promise superior performance and diverse applications in preventative healthcare.

Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company develops solutions for various medical imaging modalities, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. Lunit aims to enhance clinical decision-making for physicians by leveraging machine learning technology to provide accurate and consistent diagnoses. Its product offerings include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which includes AI-powered biomarkers for immuno-oncology. Lunit's deep learning technology has been recognized for its capabilities, ranking among the top in prestigious image recognition competitions, highlighting its innovative approach to processing medical imaging data and utilizing weakly labeled data for improved pattern recognition.

Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.

PuREC is a biotechnology company focused on developing culture technology to enhance the efficacy of medical treatments. The company's innovative approach involves rapidly evolving cell therapies and mesenchymal stem cell therapies. PuREC's technology is particularly applied in two critical areas: addressing hypophosphatasia, a rare bone-formation deficiency in newborns, and treating spinal canal stenosis, which is caused by disc herniation in the spine. By leveraging advanced therapeutic techniques, PuREC aims to empower clients in their fight against various diseases and contribute to advancements in transplantation medicine.

Junten Bio is focused on the research and development of cell-based therapies utilizing regenerative medicine technology. The company aims to enhance medical treatment options by investigating the mechanisms of immune rejection in vivo. Through its work, Junten Bio develops innovative cellular solutions that address the side effects associated with the use of immunosuppressive agents following organ transplantation. By improving patient outcomes and quality of life, the company seeks to reduce overall medical expenses related to transplant procedures.

LPixel Inc. specializes in developing advanced image analysis software solutions for life science research. Established in 2014 as a spin-out from the University of Tokyo, the company offers a range of products, including LPixel ImageJ Plugins, which assist researchers in analyzing life science images, and LP-exam, a tool designed to detect image manipulations and plagiarism. Additionally, LPixel provides IMACEL, a cloud-based image analysis system that utilizes artificial intelligence to perform morphological analysis, calculate cell counts, and classify images automatically. The company also focuses on creating software solutions to support cancer diagnoses and offers educational programs for researchers and students in the life sciences field. Based in Tokyo, LPixel is committed to enhancing research efficiency through innovative technology.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, focused on developing innovative therapeutic products utilizing its proprietary delivery technology. Founded in 2016, the company specializes in the ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract, eliminating the need for encapsulation. Suono Bio aims to transform the treatment of challenging diseases, particularly those involving inflammatory-mediated conditions, by enabling efficient and effective delivery of therapeutics across various tissues. This technology has the potential to enhance patient recovery from gastrointestinal diseases by ensuring that treatments reach their intended targets quickly and effectively.

PePerseus Proteomics is a drug discovery biotechnology venture that uses advanced antibody technology to pursue superior antibody production technology and create new medicines powerfully for people around the world who are waiting for better medical care .

IS Japan, founded in 1989, manufactures in vitro fertilization products, products for cell culture, and products for research on regenerative medicine and cell therapy, and distributes Irvine Scientific's products in and outside Japan.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is a biotechnology company based in Tokyo that focuses on developing innovative therapies for serious genetic disorders. Founded in 2016, the company leverages its proprietary CRISPR-GNDM technology, which allows for precise modulation of gene expression and histone modification without the need for traditional gene editing methods. Modalis Therapeutics aims to address unmet medical needs related to orphan genetic diseases, building a robust intellectual property portfolio in collaboration with the University of Tokyo.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Cyfuse Biomedical K.K. is a biotechnology company based in Tokyo, Japan, that specializes in the research, development, and commercialization of tissue fabrication systems and cell-based products. Founded in 2010, the company offers 3D BioFabrication systems that utilize robotic technology to assemble spheroids into customized 3D shapes, providing innovative solutions for cell delivery in research and therapeutic applications. Cyfuse develops and licenses 3D tissue products for therapeutic use and engages in contract manufacturing for research purposes. The applications of its products include blood vessel grafts for hemodialysis access and coronary artery bypass grafts, cardiac grafts for drug toxicology and myocardial infarction therapy, cartilage grafts for surgical reconstruction, and hepatocyte grafts for drug metabolism studies and hemophilia treatment. Cyfuse Biomedical serves various research and development institutes, including universities, and has established a strategic partnership with Shibuya Kogyo Co., Ltd.

Tokiwa Bio Inc. is a Japanese company based in Tsukuba that specializes in the development and manufacturing of drugs for regenerative medicine, particularly focusing on gene therapy. Founded in 2014, the company utilizes artificially synthesized vectors to introduce multiple genes into the cytoplasm of cells without causing damage to the existing genetic material. This innovative approach facilitates the creation of gene therapy drugs aimed at treating rare diseases, including hemophilia and ischemia. In addition to its gene therapy efforts, Tokiwa Bio also produces biopharmaceuticals, antibody drugs, and research reagents, positioning itself as a key player in the biopharmaceutical industry.

BONAC specializes in research and development of nucleic acid medicines. Its services include nucleic acid drug substance manufacturing and drug development. The company was founded in 2010.

RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .

Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson's group, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM's pioneering iPSC research. Cynata's Cymerus™ platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments being investigated for such devastating diseases as osteoarthritis, Crohn’s disease and heart disease. Cynata’s proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. Cynata will use the proprietary Cymerus™ technology to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. This opens up a wide range of therapeutic and manufacturing possibilities for the Company. The Cymerus™ technology has several characteristics which makes it ideal for the development of cell-based therapeutics. Most critically, the Cymerus™ manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities. This means that Cynata will not have to constantly seek out fresh stem cell donors to fuel its manufacturing demands. This has the potential to create a new standard in the emergent arena of regenerative medicine and stem cell therapeutics and provides Cynata with both a unique differentiator and an important competitive position.

Ultra Pure Solutions, Inc. is one of the largest manufacturers of high purity chemicals in North America.

FUJIFILM TeraMedica, Inc., based in Milwaukee, WI, is a leading global healthcare informatics company specializing in vendor-neutral, enterprise-wide solutions for medical image management. Founded in 2001, the company gained recognition for deploying the first patient-centric clinical image archive at the Mayo Clinic in 2003. TeraMedica's software has since been implemented in over 600 locations worldwide, demonstrating its capacity to adapt to diverse healthcare environments. The company's focus on customer satisfaction is supported by a robust technology platform designed for flexibility and integration within healthcare enterprises.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

PePerseus Proteomics is a drug discovery biotechnology venture that uses advanced antibody technology to pursue superior antibody production technology and create new medicines powerfully for people around the world who are waiting for better medical care .

PePerseus Proteomics is a drug discovery biotechnology venture that uses advanced antibody technology to pursue superior antibody production technology and create new medicines powerfully for people around the world who are waiting for better medical care .

Dimatix is a world leader in the research, development, manufacture and sale of printheads used in industrial inkjet printers, which are increasingly being used in such fields as outdoor advertising and packaging materials. As such, the company supplies printheads and provides after-sales service to printer manufacturers and various other users. Using MEMS1, Dimatix has developed advanced piezoelectric printheads2 that feature superior quality and excellent durability.

PePerseus Proteomics is a drug discovery biotechnology venture that uses advanced antibody technology to pursue superior antibody production technology and create new medicines powerfully for people around the world who are waiting for better medical care .

Sericol is a global corporation engaged in the development, manufacturing and sale of inks for screen and package printing as well as industrial inkjet inks and materials. With inks for screen printing and wide format digital UV inkjet inks, the company maintains a leading market share position worldwide.